 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
11-17-2023
Insider Buy |
William P. Forbes
EVP, Chief Development Officer |
$1.09
CAGR »
|
$27,250.00
25,000 shares |
11-16-2023
Insider Buy |
William P. Forbes
EVP, Chief Development Officer |
$0.94
CAGR »
|
$46,995.00
50,000 shares |
11-16-2023
Insider Buy |
Ira Duarte
EVP, Chief Financial Officer |
$0.89
CAGR »
|
$75,599.00
85,000 shares |
11-16-2023
Insider Buy |
Craig A. Collard
Chief Executive Officer |
$0.92
CAGR »
|
$137,970.00
150,000 shares |
10-4-2019
Insider Buy |
Kevin C. Tang
Director |
$17.50
CAGR »
|
$4,999,995.00
285,714 shares |
10-3-2019
Insider Buy |
John Poyhonen
EVP, Chief Commercial Officer |
$17.50
CAGR »
|
$90,002.50
5,143 shares |
10-3-2019
Insider Buy |
Barry D. Quart
Chief Executive Officer |
$17.50
CAGR »
|
$79,992.50
4,571 shares |
5-22-2019
Insider Buy |
John Poyhonen
Director |
$17.55
CAGR »
|
$52,650.00
3,000 shares |
5-15-2019
Insider Buy |
Waage Christian
Director |
$18.04
CAGR »
|
$25,261.74
1,400 shares |
3-29-2018
Insider Buy |
Kevin C. Tang
Director and >10% Owner |
$26.00
CAGR »
|
$5,000,008.00
192,308 shares |
1-19-2017
Insider Buy |
John Poyhonen
Director |
$12.20
CAGR »
|
$122,000.00
10,000 shares |
1-19-2017
Insider Buy |
Kevin C. Tang
Director and >10% Owner |
$12.20
CAGR »
|
$29,999,995.20
2,459,016 shares |
6-10-2015
Insider Buy |
Kevin C. Tang
Director and >10% Owner |
$24.75
CAGR »
|
$2,999,997.00
121,212 shares |
6-2-2015
Insider Buy |
Kevin C. Tang
Director and >10% Owner |
$20.62
CAGR »
|
$3,092,285.12
150,000 shares |
6-25-2014
Insider Buy |
Kevin C. Tang
Director and >10% Owner |
$11.75
CAGR »
|
$5,999,996.50
510,638 shares |
6-25-2014
Insider Buy |
Barry D. Quart
Chief Executive Officer |
$11.75
CAGR »
|
$117,500.00
10,000 shares |
Also See: Institutional Holders of HRTX
Also See: SEC filings
Below we present the annualized performance delivered by Heron Therapeutics stock since 11-17-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Heron Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about HRTX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/20/2023 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$1.30 |
|
| End price/share: |
$2.45 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
88.46% |
|
| Annualized Gain: |
205.66% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$18,846.00 |
|
| Years: |
0.43 |
|
Heron Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Heron Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding HRTX
|
|
Free HRTX Email Alerts:
